Operating
Net gains (losses) on investments
Neurocrine Biosciences Net gains (losses) on investments decreased by 17.3% to $25.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 182.7%, from -$30.60M to $25.30M. Over 3 years (FY 2021 to FY 2024), Net gains (losses) on investments shows a downward trend with a 21.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
Positive values indicate successful investment management, while negative values reflect market volatility or poor asset performance.
Detailed definition
This captures the non-cash gains or losses realized from the sale or revaluation of equity investments and securities. I...
Peer comparison
Common for large corporations with diversified portfolios or strategic minority stakes.
Metric ID:
gain_loss_on_investmentsHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$8.20M | $28.40M | $19.90M | -$7.40M | $11.10M | $7.20M | $2.20M | $37.30M | -$40.10M | $29.00M | $1.60M | -$19.90M | -$16.90M | -$1.90M | -$30.60M | -$6.70M | $30.60M | $25.30M |
| QoQ Change | — | — | +446.3% | -29.9% | -137.2% | +250.0% | -35.1% | -69.4% | >999% | -207.5% | +172.3% | -94.5% | <-999% | +15.1% | +88.8% | <-999% | +78.1% | +556.7% | -17.3% |
| YoY Change | — | — | — | — | — | +235.4% | -74.6% | -88.9% | +604.1% | -461.3% | +302.8% | -27.3% | -153.4% | +57.9% | -106.6% | <-999% | +66.3% | +281.1% | +182.7% |
Range-$40.10M – $37.30M
Avg YoY Growth-85.3%
Median YoY Growth+15.3%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | -$30.60M | -$6.70M | $30.60M | $25.30M |
| Total | -$30.60M | -$6.70M | $30.60M | $25.30M |
Net gains (losses) on investments at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's net gains (losses) on investments?
- Neurocrine Biosciences (NBIX) reported net gains (losses) on investments of $25.30M in Q1 2026.
- How has Neurocrine Biosciences's net gains (losses) on investments changed year-over-year?
- Neurocrine Biosciences's net gains (losses) on investments increased by 182.7% year-over-year, from -$30.60M to $25.30M.
- What is the long-term trend for Neurocrine Biosciences's net gains (losses) on investments?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's net gains (losses) on investments has grown at a 21.1% compound annual growth rate (CAGR), from $20.90M to -$37.10M.
- What does net gains (losses) on investments mean?
- The profit or loss made from selling or holding financial investments.